MX2017013390A - Método para el tratamiento de cáncer pulmonar. - Google Patents
Método para el tratamiento de cáncer pulmonar.Info
- Publication number
- MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A
- Authority
- MX
- Mexico
- Prior art keywords
- fra
- patient
- lung cancer
- level
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G01N33/575—
-
- G01N33/5752—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Abstract
se proporcionan en el presente documento métodos para predecir una probabilidad de respuesta al tratamiento con un agente de direccionamiento del receptor alfa de folato (FRA) en un paciente que tiene un cáncer de pulmón que expresa FRA; también se proporcionan métodos para tratar un cáncer de pulmón que expresa FRA en un paciente con un agente de direccionamiento de FRA; los métodos implican cuantificar o determinar el nivel de expresión de FRA del paciente en una muestra biológica y comparar el nivel de expresión de FRA del paciente con un estándar de referencia utilizado para cuantificar el nivel de expresión de FRA, en donde es probable que el paciente responda al tratamiento con el agente de direccionamiento de FRA si el nivel de expresión de FRA del paciente es igual o superior al nivel de expresión de FRA de referencia; también se proporcionan kits relacionados para la predicción de la respuesta y el tratamiento de la población identificada de pacientes con cáncer de pulmón que expresa FRA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149184P | 2015-04-17 | 2015-04-17 | |
| PCT/US2016/027497 WO2016168440A1 (en) | 2015-04-17 | 2016-04-14 | Methods for treating lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013390A true MX2017013390A (es) | 2018-06-13 |
Family
ID=55809240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013390A MX2017013390A (es) | 2015-04-17 | 2016-04-14 | Método para el tratamiento de cáncer pulmonar. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180125970A1 (es) |
| EP (1) | EP3283886B1 (es) |
| JP (1) | JP2018516244A (es) |
| KR (1) | KR20170137848A (es) |
| CN (1) | CN107624071A (es) |
| AU (1) | AU2016248222A1 (es) |
| BR (1) | BR112017022320A2 (es) |
| CA (1) | CA2983126A1 (es) |
| IL (1) | IL255079A0 (es) |
| MX (1) | MX2017013390A (es) |
| RU (1) | RU2718780C9 (es) |
| SG (1) | SG11201708546UA (es) |
| WO (1) | WO2016168440A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1879922A2 (en) * | 2005-04-22 | 2008-01-23 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| US20170247449A1 (en) * | 2014-06-06 | 2017-08-31 | Kyowa Hakko Kirin Co., Ltd | Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism |
| JP7072571B2 (ja) | 2016-11-23 | 2022-05-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗葉酸受容体アルファ抗体およびその使用 |
| CN111954681B (zh) | 2018-03-13 | 2022-12-06 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| CN112955178B (zh) * | 2018-06-18 | 2025-03-11 | 免疫医疗有限公司 | 用于治疗癌症的、lif抑制剂和基于铂的抗肿瘤剂的组合 |
| CN110221052B (zh) * | 2019-06-17 | 2022-09-23 | 昆山德诺瑞尔生物科技有限公司 | Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用 |
| WO2023170216A1 (en) * | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050232919A1 (en) | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EP1879922A2 (en) * | 2005-04-22 | 2008-01-23 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| EP3130605B1 (en) | 2010-11-05 | 2020-01-08 | Eisai Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| SI2731972T1 (en) | 2011-07-15 | 2018-04-30 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
-
2016
- 2016-04-14 SG SG11201708546UA patent/SG11201708546UA/en unknown
- 2016-04-14 AU AU2016248222A patent/AU2016248222A1/en not_active Abandoned
- 2016-04-14 US US15/566,888 patent/US20180125970A1/en not_active Abandoned
- 2016-04-14 BR BR112017022320-1A patent/BR112017022320A2/en not_active Application Discontinuation
- 2016-04-14 CN CN201680028727.8A patent/CN107624071A/zh active Pending
- 2016-04-14 EP EP16718820.0A patent/EP3283886B1/en active Active
- 2016-04-14 WO PCT/US2016/027497 patent/WO2016168440A1/en not_active Ceased
- 2016-04-14 JP JP2017554475A patent/JP2018516244A/ja active Pending
- 2016-04-14 MX MX2017013390A patent/MX2017013390A/es unknown
- 2016-04-14 CA CA2983126A patent/CA2983126A1/en not_active Abandoned
- 2016-04-14 KR KR1020177032864A patent/KR20170137848A/ko not_active Withdrawn
- 2016-04-14 RU RU2017136863A patent/RU2718780C9/ru not_active IP Right Cessation
-
2017
- 2017-10-17 IL IL255079A patent/IL255079A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2718780C9 (ru) | 2020-07-08 |
| EP3283886A1 (en) | 2018-02-21 |
| US20180125970A1 (en) | 2018-05-10 |
| RU2718780C2 (ru) | 2020-04-14 |
| WO2016168440A1 (en) | 2016-10-20 |
| SG11201708546UA (en) | 2017-11-29 |
| CN107624071A (zh) | 2018-01-23 |
| RU2017136863A3 (es) | 2019-08-21 |
| EP3283886B1 (en) | 2020-01-15 |
| AU2016248222A1 (en) | 2017-11-09 |
| RU2017136863A (ru) | 2019-05-17 |
| KR20170137848A (ko) | 2017-12-13 |
| IL255079A0 (en) | 2017-12-31 |
| JP2018516244A (ja) | 2018-06-21 |
| CA2983126A1 (en) | 2016-10-20 |
| BR112017022320A2 (en) | 2018-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013390A (es) | Método para el tratamiento de cáncer pulmonar. | |
| MX2023010805A (es) | Metodos terapeuticos y de diagnostico para el cancer. | |
| MX2021009682A (es) | Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos. | |
| MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX2015011362A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| PH12020551683A1 (en) | Biomarkers for graft-versus-host disease | |
| MX2019010150A (es) | Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5. | |
| ES2721639T3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
| MX2020002553A (es) | Metodos de diagnostico y terapeuticos para el cancer. | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| MX2017011486A (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| MX2017006242A (es) | Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. | |
| MX2024001734A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
| CL2020001936A1 (es) | Métodos para el tratamiento de la atrofía muscular espinal. | |
| BR112019025056A2 (pt) | Inibidores de fgfr2 para o tratamento de colangiocarcinoma | |
| CO2020008863A2 (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| MX2025004103A (es) | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa | |
| BR112016017926A2 (pt) | ensaio para detectar periostina humana | |
| MX2020003565A (es) | Variantes de cornulina (crnn) y sus usos. | |
| CO2018011200A2 (es) | Marcador para predecir la respuesta al tratamiento del agente anticancerígeno en pacientes con cáncer | |
| ES2945782R1 (es) | Biomarcadores predictivos de autoinmunidad en pacientes tratados con alemtuzumab. | |
| UA94367U (uk) | Спосіб прогнозування незрощення перелому |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: EISAI INC. |